<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10883663</article-id><article-id pub-id-type="pmc">2374547</article-id><article-id pub-id-type="pii">6691160</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1160</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pronk</surname><given-names>L C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vasey</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sparreboom</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Reigner</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Planting</surname><given-names>A S Th</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gordon</surname><given-names>R J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Osterwalder</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Verweij</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Twelves</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, Rotterdam, The Netherlands</aff><aff id="aff2"><label>2</label>Cancer Research Campaign, Department of Medical Oncology, Beatson Oncology Centre, Glasgow, UK</aff><aff id="aff3"><label>3</label>Quintiles Oncology, Strasbourg, France; Hoffmann-La Roche, Basel, Switzerland</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: </corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>06</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>07</month><year>2000</year></pub-date><volume>83</volume><issue>1</issue><fpage>22</fpage><lpage>29</lpage><history><date date-type="received"><day>20</day><month>10</month><year>1999</year></date><date date-type="rev-recd"><day>01</day><month>02</month><year>2000</year></date><date date-type="accepted"><day>17</day><month>02</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Capecitabine and docetaxel are both active against a variety of solid tumours, while their toxicity profiles only partly overlap. This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds. Thirty-three patients were treated with capecitabine administered orally twice daily on days 1&#x02013;14, and docetaxel given as a 1 h intravenous infusion on day 1. Treatment was repeated every 3 weeks. The dose of capecitabine ranged from 825 to 1250 mg m<sup>&#x02013;2</sup>twice a day and of docetaxel from 75 to 100 mg m<sup>&#x02013;2</sup>. The dose-limiting toxicity (DLT) was asthenia grade 2&#x02013;3 at a dose of 1000 mg m<sup>&#x02013;2</sup>bid of capecitabine combined with docetaxel 100 mg m<sup>&#x02013;2</sup>. Neutropenia grade 3&#x02013;4 was common (68&#x00025; of courses), but complicated by fever in only 2.4&#x00025; of courses. Other non-haematological toxicities were mild to moderate. There was no pharmacokinetic interaction between the two drugs. Tumour responses included two complete responses and three partial responses. Capecitabine 825 mg m<sup>&#x02013;2</sup>twice a day plus docetaxel 100 mg m<sup>&#x02013;2</sup>was tolerable, as was capecitabine 1250 mg m<sup>&#x02013;2</sup>twice a day plus docetaxel 75 mg m<sup>&#x02013;2</sup>. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>phase I</kwd><kwd>pharmacokinetics</kwd><kwd>capecitabine</kwd><kwd>docetaxel</kwd></kwd-group></article-meta></front></article>


